お知らせ • Mar 19
Spyre Therapeutics, Inc. announced that it expects to receive $180.005 million in funding from a group of investors
Spyre Therapeutics, Inc. entered into a securities purchase agreement with certain institutional and accredited investors for issuance of 121,625 Series B Non-Voting Convertible Preferred Stock at a price per share of $1,480 for gross proceeds of $180,005,000 on March 18, 2024. Each preferred share is convertible into 40 shares. The securities to be issued and sold to the purchasers under the purchase agreement will not be registered under the Securities Act of 1933, as amended in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D promulgated thereunder, or under any state securities laws. The closing of the private placement is expected to occur on March 20, 2024. The transaction included participation from new and returning investors including Deep Track Biotechnology Master Fund, Ltd, Deep Track Capital, LP for 13,515 shares, RTW Master Fund, Ltd. for 3,445 shares, RTW Innovation Master Fund, Ltd. for 3,124 shares, funds managed by Rtw Biotech Opportunities Operating Ltd for 6,946 shares, Darwin Global Master Fund, Ltd., a fund managed by Darwin Global Management Limited for 11,301 shares, Farallon Capital Partners, L.P. for 2,341 shares, Farallon Capital Institutional Partners, L.P. for 2,144 shares, Farallon Capital Institutional Partners II, L.P. for 476 shares, Farallon Capital Institutional Partners III, L.P. for 17 shares, Four Crossings Institutional Partners V, L.P. for 356 shares, Farallon Capital Offshore Investors II, L.P for 4,850 shares, Farallon Capital F5 Master I, L.P. for 1,368 shares, Farallon Capital (AM) Investors, L.P. for 278 shares, funds managed by Farallon Capital Management, L.L.C., Avidity Master Fund LP, a fund managed by Avidity Partners Management, L.P. for 10,135 shares, T. Rowe Price Health Sciences Fund, Inc. for 9,672 shares, T. Rowe Price Equity Series, Inc. - T. Rowe Price Health Sciences Portfolio for 462 shares, T. Rowe Price Multi-Strategy Total Return Fund for 1 share, funds managed by T. Rowe Price Associates, Inc., Adage Capital Partners, L.P., a fund managed by Adage Capital Management, L.P. for 6,755 shares, Perceptive Life Sciences Master Fund, Ltd., a fund managed by Perceptive Advisors LLC for 6,755 shares, Blackstone Annex Master Fund L.P. for 3,040 shares, Spruce Street Aggregator L.P. for 709 shares, Cdk Associates, LLC for 1,905 shares, Third Street Holdings LLC for 122 shares, Logos Global Master Fund, LP, a fund managed by Logos Global Management, L.P. for 5,745 shares, Boxer Capital LLC for 5,745 shares, Atlas Diversified Master Fund, Ltd., a fund managed by Balyasny Asset Management L.P. for 5,065 shares, Braidwell Partners Master Fund LP, a fund managed by Braidwell LP for 2,700 shares, Biomedical Value Fund for 1,490 shares, Biomedical Offshore Value Fund, LTD. for 1,026 shares, funds managed by Great Point Partners, LLC, Cheyne Select Master Fund Icav - Cheyne Global Equity Fund, a fund managed by Cheyne Capital Management (UK) LLP for 184 shares, Woodline Master Fund LP, a fund managed by Woodline Partners LP for 2,025 shares, Walleye Opportunities Master Fund Ltd, a fund managed by Walleye Capital LLC for 1,690 shares, Affinity Healthcare Fund, LP, a fund managed by Affinity Asset Advisors, LLC for 1,690 shares, Quantum Partners LP, a fund managed by Soros Fund Management LLC for 1,690 shares, Commodore Capital Master LP, a fund managed by Commodore Capital LP for 1,350 shares, StemPoint Capital Master Fund LP for 675 shares.